Insider trade

Officer sold ~$34K of BMY shares in the open market

Traded Aug 25, 2026 · Filed Aug 26, 2026

Bristol Myers SquibbBMY

~$34K
Reported value · 500 sh @ $67.50: 17K
Holds after · shares reported: -9.5%
stock since the trade · S&P 500 -0.3%, $67.92 → $61.46 on Oct 1

Why it stands out

Bristol Myers Squibb's SVP and Controller sold $34K of Bristol Myers Squibb shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 25, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 26, 2026

Officer$25K–$100K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$33,750

Shares × reported transaction price

Timing vs results

26 days after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $67.92 on Aug 25, 2026, at its 52-week high, after a 19% rise over the previous 30 trading days

52-week range $42.60 (Oct 29, 2025) to $67.92 (Aug 25, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $56.95 on Jul 14, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Zenbexus on Aug 13, 2026, 12 days before this trade.

New drug application approved. Active ingredient: Iberdomide Hydrochloride. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+1.7%	+0.3%	+1.4%
30 days	-4.6%	-0.7%	-3.9%

Past results only. Not a forecast.

Source receipt

Record ID: 0002012588-26-000004
Filed / recorded: Aug 26, 2026, 8:17 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: BRISTOL MYERS SQUIBB CO
Issuer CIK: 14272
Ticker: BMY
Reporting person: Phil M Holzer
Relationship: Officer
Officer title: SVP and Controller
Security: Common Stock, $0.10 par value
Table: Non-derivative (Table I)
Transaction date: Aug 25, 2026
Transaction code: S
Shares / units: 500
Price per share: $67.50
Acquired / disposed: Disposed (D)
Shares owned after: 16,862
Ownership form: Direct
Amendment: No

Around the same time

Officer sold4w ago

~$403KReported value · 6,249 sh @ $64.57

25K → 19K shares held−25% of their stake

Bristol Myers Squibb's Chief Med Offr,Head of Dev sold $403K of Bristol Myers Squibb shares. Nobody planned it ahead of time.

Why it stands out Official record

Officer plans to sell ~$403K of Bristol Myers Squibb

Planned, from pay4w ago

5w ago

1,236Shares · @ $66.92

Derivative exercise or conversion — not an open-market buy.